NASDAQ NMS - GLOBAL MARKET · BCDA

+5.31% · +$0.0600 · Vol 244.2K

After hours · updated 16:14:00 ET

BioCardia Inc

Biotechnology

$1.19

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factors

Stale score · Tue Aug 25 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET · BCDA

Methodology

BCDA

BioCardia Inc

Stale score · Tue Aug 25 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET

73/100

BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

73/ 100

Veridion Score

BUY BIAS · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 25 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is BCDA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move BCDA next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 25
Score
Score moved +47
26/AVOID -> 73/BUY BIAS
Veridion score historySource

About BioCardia Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1995

Employees

Country

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$1.13

Day high

$1.21

Day low

$1.10

Previous close

$1.13

52W high